Trial Profile
Phase 1 Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 May 2024
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Aug 2024.
- 02 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Mar 2024.
- 14 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.